Stevanato Group (NYSE:STVN) Price Target Cut to $23.50 by Analysts at UBS Group

Stevanato Group (NYSE:STVN - Free Report) had its price target cut by UBS Group from $24.00 to $23.50 in a report published on Friday,Benzinga reports. They currently have a neutral rating on the stock.

Other analysts have also recently issued reports about the company. Wolfe Research assumed coverage on Stevanato Group in a research report on Friday, December 13th. They issued an "outperform" rating and a $28.00 target price for the company. Morgan Stanley reissued an "equal weight" rating and issued a $23.00 target price (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Finally, Bank of America upped their target price on Stevanato Group from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, December 13th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of €27.75 ($30.16).

Stevanato Group Stock Up 4.9 %

NYSE STVN traded up €1.02 ($1.11) on Friday, hitting €21.72 ($23.61). 581,300 shares of the stock were exchanged, compared to its average volume of 345,934. The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. Stevanato Group has a fifty-two week low of €16.56 ($18.00) and a fifty-two week high of €33.49 ($36.40). The company has a market cap of $6.58 billion, a PE ratio of 46.21, a PEG ratio of 7.18 and a beta of 0.60. The company has a 50-day moving average price of €21.38 and a 200-day moving average price of €20.54.

Remove Ads

Stevanato Group (NYSE:STVN - Get Free Report) last posted its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) EPS for the quarter, hitting the consensus estimate of €0.20 ($0.22). The company had revenue of €352.68 million during the quarter, compared to analysts' expectations of €346.26 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. Sell-side analysts anticipate that Stevanato Group will post 0.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Stevanato Group

A number of hedge funds have recently made changes to their positions in the stock. Zions Bancorporation N.A. acquired a new position in Stevanato Group during the third quarter valued at approximately $1,049,000. Sivik Global Healthcare LLC acquired a new position in Stevanato Group during the third quarter valued at approximately $2,800,000. King Wealth Management Group lifted its position in Stevanato Group by 30.2% during the third quarter. King Wealth Management Group now owns 94,800 shares of the company's stock valued at $1,896,000 after buying an additional 22,000 shares in the last quarter. Royce & Associates LP lifted its position in Stevanato Group by 45.8% during the third quarter. Royce & Associates LP now owns 343,159 shares of the company's stock valued at $6,863,000 after buying an additional 107,869 shares in the last quarter. Finally, Natixis Advisors LLC lifted its position in Stevanato Group by 20.3% during the third quarter. Natixis Advisors LLC now owns 51,343 shares of the company's stock valued at $1,027,000 after buying an additional 8,669 shares in the last quarter.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.